This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

NeoStem To Present At Multiple June Conferences

Stock quotes in this article: NBS

NEW YORK, May 28, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company will present at multiple upcoming conferences in June. In addition, Phase 1 data licensed from the University of California, San Francisco (UCSF) by NeoStem for its T regulatory cell product candidate for type 1 diabetes, is expected to be presented by Dr. Stephen Gitelman of UCSF, on June 15 at the American Diabetes Association's 74 th Scientific Sessions in San Francisco.

American Society of Clinical Oncology 50 th Annual Meeting

  • Date and Time: Sunday, June 1, 2014, 8:00 AM – 11:45 AM CDT
  • Venue: McCormick Place, Chicago, Illinois
  • Website: am.asco.org
  • Poster Presenter: Dr. Robert Dillman, Vice President of Oncology, NeoStem Oncology
  • Topic: Long-term survival for patients with detectable metastatic melanoma at time of treatment with patient-specific tumor stem cell vaccines

Jefferies Global Healthcare Conference

  • Date and Time: Monday, June 2, 2014, 11:30 AM EDT
  • Venue: Grand Hyatt, New York, New York
  • Website: www.jefferies.com/OurFirm/Conferences/325/148
  • Presenter: Dr. Robin Smith, Chairman and CEO, NeoStem
  • Topic: NeoStem Company Presentation

Lugano Stem Cell Meeting

Session 1:

  • Date and Time: Tuesday, June 23, 2014, 11:10 AM CET
  • Panelist: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: Industry Session

Session 2:

  • Date and Time: Tuesday, June 23, 2014, 11:50 AM CET
  • Speaker: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: CD34 Cell Therapy for Ischemic Tissue Repair

Session 3:

  • Date and Time: Tuesday, June 23, 2:05 PM CET
  • Panelist: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: Stem Cell Manufacturing and Characterization

Session 4:

  • Date and Time: Wednesday, June 24, 2014, 10:55 AM CET
  • Panel Chairman: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: Clinical Trials: Long Term Results and Their Impact for Future Trials

2014 BIO International Convention

  • Date and Time: Tuesday, June 24, 2014, 3:00 PM PDT
  • Venue: San Diego Convention Center, San Diego, California
  • Website: convention.bio.org/
  • Presenter: Dr. Robert Preti, Chief Scientific Officer, NeoStem and PCT; President, PCT
  • Topic: Targeting the End Game: Keys to Reaching Commercial Viability by Establishing the Right GMP Processes for Cell Therapy Clinical Trials from Processing to Delivery to the Patient

About NeoStem, Inc.

NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Targeted Immunotherapy Program, CD34 Cell Program, T Regulatory Cell Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the Company's contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 13, 2014, the Company's Current Report on Form 8-K filed with the SEC on May 8, 2014 and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: Investor Contact:
         LifeSci Advisors, LLC
         Michael Rice
         Founding Partner
         Phone: +1-646-597-6979
         Email: mrice@lifesciadvisors.com
         
         Media Contact:
         NeoStem, Inc.
         Eric Powers
         Manager of Communications and Marketing
         Phone: +1-212-584-4173
         Email: epowers@neostem.com

NeoStem Inc. Logo

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,034.16 -8.74 -0.05%
S&P 500 1,972.29 -5.51 -0.28%
NASDAQ 4,493.39 -12.4620 -0.28%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs